Novo Nordisk A/S Common Stock (NVO)

FairStock Score: 78/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $377 million in annual free cash flow (0.2% yield on market cap)
• High return on equity of 60.7% demonstrating efficient capital deployment
• Attractive 4.7% dividend yield providing steady income returns
• FairStock composite score of 80/100 places it in the top tier across value, quality, and momentum factors
• Established organization with 68,794 employees providing operational scale

Concerns

• Revenue declining at 7.6% year-over-year signals potential demand weakness or market share loss
• Altman Z-Score of 1.0 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Novo Nordisk A/S Common Stock is a large-cap healthcare company valued at $170.3 billion. The business generates $309.1 billion in annual revenue with a 8.7% net margin and $377 million in free cash flow. From a quality standpoint, Novo shows distressed Altman Z-Score of 1.0 warrants caution and extraordinary 61% return on equity. On valuation, the stock is attractively valued at 10.6x earnings, with offers a 36% margin of safety vs Graham Number of $60. Growth dynamics show revenue growing at -7.6% and profit growth of -4.7%. The 4.7% dividend yield adds an income component for patient holders. Our composite FairStock Score of 80/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Novo's consistent 61% ROE at just 11x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $377 million in annual free cash flow (0.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Sluggish -8% growth in a large-cap company leaves the stock vulnerable to de-rating if the market rotates toward higher-growth opportunities.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer